GNLX:NASDAQ
Genelux Corp
USD 2.56
arrow_upward
+1.19%(+0.030) 1H
USD 2.56
0.00% (0.00)
bedtimeSelepas waktu pejabat
Ditutup: 21 Sep, 4:00:01 PTG GMT-4 · USD
search
Semua simbol
1H
5H
1B
6B
TSS
1T
5T
MAKS
| Simbol | Harga | Perubahan | % Perubahan |
|---|
insights_autoMenjana cerapan popular untuk GNLX...
Buka
USD 2.57
Tinggi
USD 2.58
Rendah
USD 2.51
Permodalan Pasaran
115.83J
Purata volum
331.27K
Volum
197.29K
tgi 52 mgu
USD 8.54
rdh 52 mgu
USD 2.29
EPS
-USD 0.87
Beta
0.57
Syer tertunggak
45.24J
Bilangan pekerja
26
Buka
USD 2.57
Tinggi
USD 2.58
Rendah
USD 2.51
Permodalan Pasaran
115.83J
Purata volum
331.27K
Volum
197.29K
tgi 52 mgu
USD 8.54
rdh 52 mgu
USD 2.29
EPS
-USD 0.87
Beta
0.57
Syer tertunggak
45.24J
Bilangan pekerja
26
Profil
Genelux Corporation is a publicly traded late clinical-stage company developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company’s most advanced product candidate, Olvi-Vec, is a proprietary, modified strain of the vaccinia virus, a stable DNA virus with a large engineering capacity.
The core of Genelux’s discovery and development efforts revolves around the company's proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.
The company is currently entered its pivot Phase 3 study in Platinum resistant/refractory ovarian cancer. Trial design based on VIRO-15 Phase 2 trial which showed independent anti-tumor activity of Olvi-Vec and reversal of platinum resistance in the TME. Wikipedia
Perihal Genelux Corp
CEO-
Pekerja26
Diasaskan2001
Ibu pejabatWestlake Village, California, Amerika Syarikat
Sektor-
Laman webgenelux.com